LENZ THERAPEUTICS, INC. Payments to Acquire Marketable Securities
LENZ THERAPEUTICS, INC. (LENZ) reported Payments to Acquire Marketable Securities of $28.13 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2024-02-27
- LENZ THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2023-12-31 was -$1.00K, a 100.00% decline year-over-year.
- LENZ THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- LENZ THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2023-06-30 was $1.00K, a 100.00% decline year-over-year.
- LENZ THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2023-03-31 was $28.13M, a 83.20% decline year-over-year.
- LENZ THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2023 was $28.13M, a 93.06% decline from fiscal 2022.
- LENZ THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2022 was $405.52M.
- LENZ THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2021 was $0.00.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$1.00K derived: sum of 2 quarters · filed 2024-02-27 | $0.00 derived: sum of 3 quarters · filed 2024-02-27 | $28.13M 10-K · filed 2024-02-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $1.00K derived: sum of 2 quarters · filed 2023-11-13 | $28.13M 10-Q · filed 2023-11-13 | $93.83M derived: sum of 4 quarters · filed 2024-02-27 |
| 2023-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $28.13M 10-Q · filed 2023-08-14 | $93.83M derived: sum of 3 quarters · filed 2024-02-27 | $179.42M derived: sum of 4 quarters · filed 2024-02-27 |
| 2023-03-31 | $28.13M 10-Q · filed 2023-05-11 | $93.83M derived: sum of 2 quarters · filed 2024-02-27 | $179.42M derived: sum of 3 quarters · filed 2024-02-27 | $266.25M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-12-31 | $65.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $151.29M derived: sum of 2 quarters · filed 2024-02-27 | $238.13M derived: sum of 3 quarters · filed 2024-02-27 | $405.52M 10-K · filed 2024-02-27 |
| 2022-09-30 | $85.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $172.42M derived: sum of 2 quarters · filed 2023-11-13 | $339.81M 10-Q · filed 2023-11-13 | $339.81M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $86.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $254.22M 10-Q · filed 2023-08-14 | $254.22M derived: sum of 3 quarters · filed 2023-08-14 | $254.22M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $167.39M 10-Q · filed 2023-05-11 | $167.39M derived: sum of 2 quarters · filed 2023-05-11 | $167.39M derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $0.00 derived: sum of 2 quarters · filed 2023-03-20 | $0.00 10-K · filed 2023-03-20 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |